While rates of cancer diagnosis under age 50 have risen in recent years, this has not translated into increased cancer ...

New Medicaid eligibility rules may cause more than a million missed cancer screenings, and more than 100 preventable deaths, ...

Immuneering (IMRX) has attracted fresh attention after reporting updated Phase 2a data for atebimetinib in first line ...

Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts.

Tippie business analytics professor Patrick Fan isn’t a physician, but his research and collaboration with health care ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endometrial cancer. The biotech reported a 50% unconfirmed response rate, beating the expectations of William Blair ...

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

Source: Getty Images Breast cancer is the second most common cancer affecting American women and the second leading cause of cancer death in women. These numbers are higher than estimates from 2023, ...

Since last summer the Virginia Department of Health has been investigating a potential pediatric cancer cluster in Southwest ...

The overall response rate (ORR) is 35%; this increases to 42% when including unconfirmed responses Narmafotinib continues to be well tolerated by patients with the adverse effect profile of the ...

Cancer registrars throughout the world will join their colleagues, fellow medical professionals, and community leaders to observe the 25th annual National Cancer Registrars Week (NCRW), April 5–9, ...